Member Info for Saxondale

Just went to top up a couple of k , quoted £3.54
Went to buy and ended up paying £3.50
A second later I just tried a dummy sell and they are offering me £3.55 to sell ?

Usually goes the other way when I press BUY

At the end of Proactive interview , his mind was running faster than his mouth .
Imagine trying to phrase a sentence in your second language , whilst being diplomatic , and knowing you can't spill any beans .
Meanwhile , me and probably at least 4 others here are analysing every twitch he makes .Its hilarious .
When he finally lets the cat out of bag he'll probably shed a tear , and so will I .

Good summary Q , yeah there was something Markku said in the interview , I couldn't work out what he said , but something about how doctors were keen to recruit as there was nothing else to try . So that must be those 2 cohorts you mention .
Good that they are also recruiting ' fresher ' patients .
The ones they have had in the past so we hear , have often had so many treatments they probably glow in the dark .
I read from this that Faron are moving up the food chain in the pecking order for patient trials.
You don't get much more prestigious than Harvard . Boston is the epicenter of the cream of US medical talent ( and money )

It's official - Markku would be useless at poker .

Maximum amounts given a grants
Non diluting funds
Great for shareholders
News from WHO /Remap any day
USA Trial - they want the US involved
US trial providing regulatory material for marketing approval

We are in safe hands

Great summary Itsall thanks .

I didn't get to see anything of webcast - but thanks all for the updates .
Looking forward to tomorrow 2 RNS's !
So much going on , probably won't be the first multiple day .

That would have been 5000 man having a pack of 5 early on to flog on the Nasdaq .
When some REALLY big news drops , I don't mean to exaggerate , but with the demand coming from two markets now , this price will seriously go mental .

Buys vs Sells were 10:1 earler

Theyve gotta up the price if they want people to let them go in any volume , although why would you , if you can afford to hold , things are about to get interesting this summer .

5000 man paying through the nose today ( about time )

LSE £17k sold , £191k bought .
Nasdaq up 8% at the moment ( 48k euros )

Wow its been a long time waiting for a rise .
About time we got back to pre first launch prices - £7.50 odd .
Faron deserve to be miles higher with Clevegen too.
Still cheap at £3.75 - I bought plenty higher as did many others .

It took 2 RNS's to get the price to actually go up rather than down .
Is that like flushing the loo twice , moves the job on a bit quicker lol

Hibiscus looks like a COVID trial , but awaiting the regulatory approval .
Caliber is an ARDS trial - that has approval ( nothing mentioned about this moving forward )

I'm reading between the lines that the REMAP / Solidarity will get T off the line and into production , as good results will allow FDA to grant market approval - probably along with phase 4 style trials .
Proving that T works on Covid patients , should in my mind tick the box for ARDS - as that is what they are treating - its just that the patients got into ICU because of COVID .

Still much to confirm and find out .

Interesting that Hibiscus is a USA trial . That could be a big clue - Just feels like a direction change ( in a good way )

I think being on the Nasdaq gets you listed in various other markets , some as OTC ( Over the Counter trades ) - more of a shop window and look up than an active trading platform .
But should all hell break loose - surely they will hopefully be moving up to main markets anyway !!

Apparently the INN has to be a totally different name to the companies drug name to make sure it isn't confused.

It was selected as a candidate name back in late 2018 - so to have it granted now means one thing...

The Organization collaborates closely with national nomenclature committees to select a single name of worldwide acceptability for each active substance that is to be marketed as a pharmaceutical

So we get a dedicated phase 2/3 USA trial for T now ( Hibiscus) - Faron says - Commencement of the trial remains subject to finalisation of funding arrangements and regulatory approval. Further announcements will be made in due course.
So who would fund a prestigious Harvard based US trial ?
Surely you don't embark on a third high profile trial without knowing you are being successful so far ?
More on C too - just keeps getting better , expanding cohorts etc

More news than I was expecting overall - hopefully the Q&A will fill in some blanks !

And remember Faron have been here before , preparing for market back in 2017/18 .
They know the route , and the people who need to be involved to bring this to a global market.
Back in 2017 they RNS that :
Collaboration was initiated with INC Research/inVentiv Health - a global biopharmaceutical solutions organization with end-to-end clinical development and commercialization capabilities - to develop the pre-launch commercialization strategy for Traumakine.
This group is now known as is Syneos Heath ( https://www.syneoshealth.com/)
I've mentioned them before - as they would have been guiding Faron through all stages of commercialisation .
So they have had a full dress rehearsal .
Anyway - lets see what tomorrow brings
Maybe no bombshells - but we are only moving one way in the long term .

And Faron supplied WHO with 2000 treatments of Traumakine initially .
So much to catch up with tomorrow

Not to forget the 14 million euro placing.
Strong position indeed.

So Faron will get this done without any 3rd party JV - just a super low interest loan from Business Finland
7 year loan - no payments for 3 years
Still 100% owned
Maximises Value to shareholders
No impact of Clevegen project budget
I'm guessing the new process must be the freeze dried lyophilised manufacturing - for global distribution.
Why would they get a 2million euro low interest loan if you weren't pretty sure this wasn't going to be needed.
I wonder who they will be using ?
AGC Biologics ?
This is a big step.

Manufacturing update on T - looks like the wheels are turning !!

aron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to initiate a new state of the art process for the manufacturing of interferon (IFN) beta-1a. To support this, Faron has received a €2,100,000 low interest rate loan from Business Finland, the governmental innovation financing agency of Finland ("Loan"). The Loan funds will be used to develop and select a new cell line that can be used for future commercial scale production of Faron's human IFN beta-1a.